CluenexMerck & Co Inc MRK
Merck & Co Inc scores average on business quality (5.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Merck & Co Inc does
Merck makes money by developing and selling prescription pharmaceuticals and vaccines, anchored by oncology treatments paid for by healthcare systems and insurers globally. Growth relies heavily on expanding its core drug pipeline to offset upcoming patent cliffs.
- What it does best
Merck dominates oncology through Keytruda, generating massive cash flow backed by a gross margin of 77% that outperforms peers like JNJ at 68%. This drug franchise relies on deep clinical integration and patent walls that take decades to replicate.
- The main risk
The looming loss of exclusivity for Keytruda threatens a significant portion of total revenue. If the pipeline fails to launch replacement therapies before the patent cliff hits, growth will stall.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins at 16% trail peers like LLY at 50% due to heavy R&D spending, limiting near-term earnings power while keeping the company heavily reliant on pipeline success.
A top-quartile gross margin of 78% reflects an entrenched IP moat protecting its drug portfolio from generic entry, though patent expirations limit long-term stickiness without new blockbusters.
Revenue growth crawls at 1.3%, fading significantly compared to historical periods and lagging sector peers as older blockbusters mature without explosive new replacements.
Debt-to-equity sits at 0.9, supported by $16.1B in free cash flow, but net debt has risen to $34.8B as the company funds pipeline deals and shareholder returns, making the balance sheet softer.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
5 sold $30.0M outside pre-planned sales.
Our sealed record on MRK
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Merck & Co Inc scores average on the Cluenex quality check (5.3 of 10), measured against its own industry. Profitability is fair, moat strong, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 5 sold $30.0M outside pre-planned sales.
Oct 29, 2026.
See MRK today
- Today's verdict on MRK, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Merck & Co Inc (MRK)”, https://cluenex.com/stocks/mrk/, data as of Oct 10, 2026.